Jan 23 (Reuters) - Macrogenics Inc:
* MACROGENICS ANNOUNCES CONTINUATION OF SOPHIA STUDY OF MARGETUXIMAB BASED ON COMPLETION OF INTERIM FUTILITY ANALYSIS
* MACROGENICS INC - U.S. FDA HAS GRANTED FAST TRACK DESIGNATION FOR INVESTIGATION OF MARGETUXIMAB
* MACROGENICS - GRANTED FAST TRACK DESIGNATION FOR INVESTIGATION OF MARGETUXIMAB FOR TREATMENT OF PATIENTS WITH METASTATIC/ LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER
* MACROGENICS INC - ANNOUNCED COMPLETION OF A PRE-PLANNED INTERIM FUTILITY ANALYSIS OF PHASE 3 SOPHIA TRIAL
* MACROGENICS INC - AN INDEPENDENT DATA SAFETY MONITORING COMMITTEE (DSMC) HAS RECOMMENDED THAT SOPHIA STUDY CONTINUE AS PLANNED WITHOUT MODIFICATION Source text for Eikon: Further company coverage:
 